APA (7th ed.) Citation

MD, M., DS, K., H, L., FJ, M., PW, K., MA, F., . . . MR, S. (2007). Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25(9), 1038. https://doi.org/10.1200/JCO.2006.07.3361

Chicago Style (17th ed.) Citation

MD, Michaelson, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, and Smith MR. "Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-releasing Hormone Agonist-induced Bone Loss in Men with Prostate Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 25, no. 9 (2007): 1038. https://doi.org/10.1200/JCO.2006.07.3361.

MLA (9th ed.) Citation

MD, Michaelson, et al. "Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-releasing Hormone Agonist-induced Bone Loss in Men with Prostate Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 25, no. 9, 2007, p. 1038, https://doi.org/10.1200/JCO.2006.07.3361.